Clinical Trial Setback Sends Intellia Shares into a Tailspin
A significant adverse event within a late-stage clinical program has triggered a crisis for Intellia Therapeutics, following regulatory action by the U.S. Food and Drug…
Breaking news and expert insights on markets, stocks, and cryptocurrencies